Association of Plasma Angiogenin With Risk of Incident End-Stage Kidney Disease in Individuals With Type 2 Diabetes.

Abstract

We investigated the association between plasma angiogenin and the risk of progression to end-stage kidney disease (ESKD) in patients with type 2 diabetes (T2D) and attempted to infer the causal relationship between plasma angiogenin and chronic kidney disease. A total of 1,863 outpatients with T2D were included in this prospective cohort study. ESKD was defined as a composite of progression to sustained estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2, maintenance dialysis, or death due to renal causes. The secondary outcome was rapid kidney function decline defined as a eGFR decline of 5 mL/min/1.73 m2 or greater per year. Over a median follow-up of 9.3 years, 125 incident ESKD events were identified. Elevated plasma angiogenin levels were associated with an increased risk of incident ESKD (adjusted hazard ratio 1.25 [95% CI 1.01-1.55], per 1 SD) independent of cardiorenal risk factors including baseline eGFR and albuminuria. A high level of plasma angiogenin was also associated with an increased risk for rapid kidney function decline (adjusted odds ratio 1.31 [95% CI 1.07-1.61], per 1 SD). A two-sample Mendelian randomization approach suggested a potential causal relationship between plasma angiogenin and chronic kidney disease. Plasma angiogenin may be a novel biomarker and potential therapeutic target for progressive kidney disease in patients with T2D. We investigated the association of plasma angiogenin with the risk of incident end-stage kidney disease (ESKD) in patients with type 2 diabetes. A high level of plasma angiogenin is independently associated with an increased risk for incident ESKD. A two-sample Mendelian randomization analysis suggested angiogenin may be causally involved in pathogenesis of chronic kidney disease. Plasma angiogenin may be a novel biomarker and potential therapeutic target for treatment of progressive kidney disease in patients with diabetes.